Background Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …

Abstract Purpose Anti-PD-1/PD-L1 blockade can restore tumour-specific T-cell immunity and
is an emerging therapy in non-small-cell lung cancer (NSCLC). We investigated the …

Aim: We evaluated the metabolic characteristics of small-sized lung cancer using 18F-
fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG …

Purpose This study aimed to evaluate the role of 18F-fluorodeoxyglucose (18F-FDG)
positron emission tomography (PET)/computed tomography (CT) in expression of tumor …

Purpose In the present study, we aimed to evaluate the expression of programmed death-
ligand 1 (PD-L1) in patients with non-small cell lung cancer (NSCLC) by radiomic features of …

Abstract Programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1)
have been identified as novel targets of immunotherapy of lung cancer. In present study, we …

Background In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …

Objectives Programmed cell death-ligand 1 (PD-L1) is expressed on tumor cells (TC) and
tumor-infiltrating immune cells (IC). We conducted a retrospective study to investigate the …

Background Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in
patients with previously treated non-small cell lung cancer. However, little is known about …

Combined chemotherapy plus programmed death-1 (PD-1) blockade is an established
treatment against patients with advanced non–small cell lung cancer (NSCLC). However, a …